Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
12.5 USD | -1.54% | +2.54% | -44.80% |
15/05 | Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
22/03 | HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-44.80% | 61Cr | |
+7.30% | 11TCr | |
+11.01% | 11TCr | |
+0.96% | 2.23TCr | |
-12.19% | 2.22TCr | |
-5.52% | 1.94TCr | |
-37.85% | 1.79TCr | |
-5.99% | 1.72TCr | |
+7.05% | 1.43TCr | |
+34.83% | 1.25TCr |
- Stock Market
- Equities
- CABA Stock
- News Cabaletta Bio, Inc.
- Cabaletta Bio Secures Orphan Drug Designation for Myositis Treatment